Ventsislav Dobrev’s Post

Are Digital Therapeutics Dead? ABHI Executive Director, Digital Health Andrew Davies attended the HLTH Europe Startup Stage where the future of this industry was a hot topic💡 Some Digital Therapeutics businesses have ceased to operate, but that is to be expected from an immature sector as innovators find their feet and discover the value of their product. 📈 However, there is an increasing number of new and exciting products for the Digital Therapeutics industry and as maturity continues, we will continue to see more innovative solutions developed. There must be flexibility depending on disease state, modality, and geography and, critically, value must be proven! How else can the Digital Therapeutics business model be made more sustainable? Visit our resource hub for insightful reports, whitepapers and webinars designed to assist the growth of HealthTech SMEs 👉 https://lnkd.in/eXDUAMPb  #Innovation #Healthcare #HLTH #medtech #digitalhealth #healthtech

Big Pharma is absolutely crucial for the #success of digital health. Their resources, expertise, and established networks play a vital role in driving innovation and adoption. Let's take a look at few examples: 1. Johnson & Johnson: They have been investing in digital health technologies like Health Partner, a personalized coaching platform for patients with chronic conditions. It's all about improving patient outcomes through digital solutions! 2. Novartis: They've partnered with tech companies to develop digital therapeutics. For instance, their collaboration with Pear Therapeutics led to the creation of reSET, a prescription digital therapeutic that helps treat substance use disorder. It's a powerful combination of traditional medications and software-based treatments. 3. Pfizer: They're leveraging digital health to enhance clinical trials. By using wearable devices and mobile apps, they collect real-time data from patients, making the trial process more efficient and accurate. It's all about advancing medical research! 4. Roche: Roche has been at the forefront of digital health with their efforts in personalized healthcare. They have developed digital solutions that integrate diagnostics, data analytics, and therapy to provide tailored treatment options for patients. Their aim is to improve patient outcomes through precision medicine. 5. Sanofi: Sanofi is actively investing in digital health technologies to enhance patient care. They have collaborated with various tech companies to develop digital tools and platforms that support disease management, medication adherence, and remote patient monitoring. Their focus is on empowering patients and healthcare providers with innovative digital solutions. These examples highlight how Big Pharma is embracing digital health, revolutionizing healthcare, and making a positive impact on patients' lives. It's an exciting time for the industry, and these advancements are just the beginning! 😄🌍💊 #digital #digitalassets #digitalhealth #innovation #digitalhealthsolutions #healthcare #johnsonandjohnson #pfizer #novartis #roche #sanofi

Interested in what our previous winners had to say about their experience as a Best in Class Award recipient? Take a look at what Kuldeep Singh Rajput, CEO & Founder of Biofourmis, had to say! Biofourmis brings quality care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Keep making a difference Biofourmis! #digitalhealth #healthcare #biomarkers #biotech

Digital health is a dynamic, growing market. Traditional #pharmaceutical and device developers are expanding aggressively into the space and have begun to diversify by developing #digitalhealth products, either on their own or in partnership with digital technology companies. Digital health products are widely used for the prevention, diagnosis, treatment, and management of health and disease. The introduction of digital medicines—and, more recently, #digitaltherapeutics (DTx)—has begun to influence the treatment and management of certain diseases. Driven by advances in technology and increased acceptance of telehealth, digital medicines and DTx are poised to become an integral part of the healthcare model. By Premier Consulting

3 bets for the European healthcare system in the next 16 years (or before): 🔮 - People will have easy online access to their private health records and decide who can access their data and how it's used. 📱 - Pharmaceutical companies will use AI throughout their operations to boost productivity and enable the delivery of 5P medicine. 💊 - Healthcare providers will use digital tools to track patient progress and automatically guide citizens to the appropriate care. There are already great innovations in the latter. - Doccla (UK) Europe's leading virtual hospital, founded by Dag Larsson. In 2023 Bertelsmann Investments invested €5 million in the company. - Nabla (France) provides doctors with an AI-powered tool that generates clinical notes from patient consultations. It raised €22 Million in Jan/2024 led by Cathay Innovation, with participation from ZEBOX Ventures. In this article, I delve into what the European healthcare system might look like in 2040. 👉 https://lnkd.in/eGYYFWbG Enjoy the reading! #Health #healthtech #biotech #innovation

One of my favorite conferences in healthcare is happening today in NYC: The Financial Times US Pharma and Biotech Summit. Influence and impact in the healthcare industry is constantly shifting due to advancing technology, customer expectations, and policy reforms. I will be participating in an important panel discussion "Connecting with Patients and Redefining the Relationship" with: Eden Wells, Debra Jennings, Zachariah Reitano, and Oliver Barnes. Not only will I get to share my insights on how pharma companies, insurers, and other stakeholders are adapting to the changes and evolving their relationships with their patients, but I get to learn different aspects of this topic from my fellow panelists - this is actually my favorite part! #FTPharma #PatientCentricity

How do we ensure the success of accelerators in the ever-changing landscape of DTx and pharma R&D? Join this roundtable with our host Xènia Riasol and anchors, Jochen Hurlebaus and Sophie P. to discuss: 💬 How can accelerators address challenges in clinical validation and healthcare system integration? 💬 What factors contribute to the success of the accelerator program in nurturing innovation in pharma and DTx? 💬 How can accelerators ensure the sustainability and scalability of innovations, especially when integrating them into existing healthcare systems? Apply to attend ➡️ https://lnkd.in/e7WtdDPe #DTx #pharma #startups

Some insightful findings here in work by my previous colleagues at ZS around willingness to invest in SaMD. According to their survey of pharma, medtech and health tech execs, a strong majority expected their companies' investments in SaMD to increase over the next 2-3 years. This is an encouraging proof point given the current tighter market conditions #digitalhealth #healthtech #samd #healthcare https://lnkd.in/ehSrj98y

Telehealth, health tech, and health analytics companies focused on digital innovation will attract continued investor interest. In the more attractive parts of health industries, dealmakers, while remaining selective, appear eager to pursue high-quality assets which may in turn unleash some pent-up M&A demand. Read more in our global M&A outlook: https://pwc.to/3S6JONI #PwCDeals #ValueCreation #digital

Discover how the partnership between Roche (Philippines) Inc. and PLDT Enterprise is revolutionizing the healthcare industry through digital innovation in the exclusive interview with Roche Philippines General Manager and President of the Pharmaceutical and Healthcare Association of the Philippines (PHAP), Dr. Diana Edralin, MD, DPCOM Edralin on the prime news talk show, “Agenda with Cito Beltran.” Click here to watch: https://lnkd.in/g_r8GHiS The collaboration was crucial during the pandemic, with the implementation of the Project Extension for Community Healthcare Outcomes or Project ECHO in its pilot run in Guagua, Pampanga, and Samal, Bataan. Project ECHO brings the power of virtual technology to enhance the healthcare landscape by upskilling barangay healthcare workers through an innovative telementoring program. Breast cancer patients were also empowered in their navigation journey through the Patient Helpline, a hotline that provides them access to critical information on disease awareness, nearby facilities and services, available funding and treatment, and support groups.  By harnessing effective digital solutions in order to reach more Filipinos and further expand access to innovative quality healthcare, Roche Philippines and PLDT Enterprise were able to catalyze significant impact on the healthcare ecosystem.  #FurtherTogether #roche #pldtenterprise #healthinnovation #digitalsolutions #digitalhealth #ProjectECHO #patientempowerment